Tregs Immunotherapy

large Image
Tumor-infiltrating regulatory T cells can suppress effector T cells specific for tumor antigens. De Simone et al. (2016) demonstrate that tumor-infiltrating Treg cells display specific gene signatures that were also validated at the single-cell level. These data can contribute to dissect the molecul…

The arch-nemesis to cancer immunotherapies (checkpoint, cytokine, genetic/epigenetic, cellular) is not the cancer, but one of the immune system’s own: the regulatory T-cells (Tregs).

They are the counterbalance to the powerful and destructive helper and cytotoxic T-cells: the Yin to the Yang, the Dark side to the Light. Good for tolerising autoimmunity and transplant, bad for eradicating cancer and infection.

It is not easy to target and isolate them. They share the same checkpoints (CTLA4, PD-1), are stimulated by the same cytokines (IL2), and they can powerfully neutralise even powerfully activated helper/cytotoxic/NK T-cells.

Not easy, but not impossible. The TIGIT checkpoint can be targeted. So can FOXP3. But overdo it, and autoimmunity can kill too.